Spanish Biotech Platform
Plataforma de Mercados Biotecnológicos
More than 40% of oral drugs show low solubilty
40% of the oral drugs, in development, are poorly soluble, causing major attrition rates at late stage of development, due to lack of efficacy and toxicity.
Recently, many strategies have been developed in order mitigate adverse effects during toxicology studies. One of the options could be to integrate the solid state studies during formulation, offering the possibility to select the best candidates with the adequate physicochemical properties and therefore the risks can be minimized during the costly and lengthy development of new drugs. Crystal engineering provides solutions in order to identify the right candidates and design an optimal life cycle management”